The Claim
Plasma p-tau217 levels measured by the DiSMS and LyMedivh™ AXL assays are significantly elevated in individuals with mild cognitive impairment due to Alzheimer’s disease compared to cognitively unimpaired controls, with area under the curve values of 0.941 and 0.957 respectively, indicating these assays detect Alzheimer’s pathology at the earliest symptomatic stage.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Blood tests measuring p-tau217 using the DiSMS and LyMedivh™ AXL assays show higher levels in people with mild cognitive impairment from Alzheimer’s disease than in people without cognitive impairment, and these tests accurately distinguish between the two groups.
See the scientific wording
Plasma p-tau217 levels measured by the DiSMS and LyMedivh™ AXL assays are significantly elevated in individuals with mild cognitive impairment due to Alzheimer’s disease compared to cognitively unimpaired controls, with area under the curve values of 0.941 and 0.957 respectively, suggesting these assays can detect Alzheimer’s pathology at the earliest symptomatic stage.
Abnormal tau proteins clump inside brain cells, become chemically modified, and leak into the bloodstream, where they can be measured as a sign of early brain damage from Alzheimer’s.
What the research says
1 studyThis study found that two blood tests can accurately spot early signs of Alzheimer’s in people with mild memory problems by measuring a specific protein called p-tau217. The tests correctly identified most cases and rarely gave false alarms.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.